nach oben

Current Hepatology Reports

Erschienen in:

04.11.2016 | Hepatic Cancer (A Singal and A Mufti, Section Editors)

Contrast-Enhanced Ultrasound (CEUS) for the Diagnosis and Management of Hepatocellular Carcinoma: Current Status and Future Trends

verfasst von: Christopher D. Malone, Robert F. Mattrey, David T. Fetzer

Erschienen in: Current Hepatology Reports | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review discusses the use of contrast-enhanced ultrasound (CEUS) for liver lesion detection and characterization focusing on hepatocellular carcinoma (HCC). It reviews the uses of CEUS in managing patients with HCC, such as in image-guided intervention, assessment of tumor viability after locoregional treatment, and differentiation of bland from tumor thrombus. Finally, it highlights potential future uses of microbubbles in targeted HCC detection and drug delivery.

Recent Findings

The high temporal resolution of ultrasound relative to CT and MRI and its sensitivity to microbubbles enables precise analysis of enhancement profiles at miniscule contrast doses, enabling confident diagnosis of HCC and differentiation of HCC from other benign and malignant hepatic lesions.

Summary

CEUS has gained widespread acceptance worldwide for the diagnosis and management of patients with HCC. CEUS is poised to make a large clinical impact in the USA given the recent Food and Drug Administration approval of a CEUS agent for use in liver imaging.

Mattrey RF, Scheible FW, Gosink BB, Leopold GR, Long DM, Higgins CB. Perfluoroctylbromide: a liver/spleen-specific and tumor-imaging ultrasound contrast material. Radiology. 1982;145(3):759–62.CrossRefPubMed

Mattrey RF, Strich G, Shelton RE, Gosink BB, Leopold GR, Lee T, et al. Perfluorochemicals as US contrast agents for tumor imaging and hepatosplenography: preliminary clinical results. Radiology. 1987;163(2):339–43.CrossRefPubMed

First Approval by U.S. Food and Drug Administration for Contrast Enhanced Ultrasonography of the Liver Received by Bracco Diagnostics Inc. for LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use [press release]. 2016.

Schneider M. Characteristics of SonoVue trade mark. Echocardiography. 1999;16(7, Pt 2):743–6.CrossRefPubMed

Yanagisawa K, Moriyasu F, Miyahara T, Yuki M, Iijima H. Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells. Ultrasound Med Biol. 2007;33(2):318–25.CrossRefPubMed

•• Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolsoe CP, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver—update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol. 2013;39(2):187–210. Excellent summary of indications, technical considerations, and imaging findings of liver lesions in general.CrossRefPubMed

Platts DG, Luis SA, Roper D, Burstow D, Call T, Forshaw A, et al. The safety profile of perflutren microsphere contrast echocardiography during rest and stress imaging: results from an Australian multicentre cohort. Heart Lung Circ. 2013;22(12):996–1002.CrossRefPubMed

Krix M, Kiessling F, Farhan N, Schmidt K, Hoffend J, Delorme S. A multivessel model describing replenishment kinetics of ultrasound contrast agent for quantification of tissue perfusion. Ultrasound Med Biol. 2003;29(10):1421–30.CrossRefPubMed

Phillips P, Gardner E. Contrast-agent detection and quantification. Eur Radiol. 2004;14 Suppl 8:P4–10.PubMed

10.

Mattrey RF, Kono Y. Parenchymal enhancement on gray-scale in normal and pathologic tissues. Eur Radiol. 1999;9 Suppl 3:S359–63.CrossRefPubMed

11.

Kono Y, Mattrey RF. Ultrasound of the liver. Radiol Clin N Am. 2005;43(5):815–26. vii.CrossRefPubMed

12.

Lucidarme O, Kono Y, Corbeil J, Choi SH, Mattrey RF. Validation of ultrasound contrast destruction imaging for flow quantification. Ultrasound Med Biol. 2003;29(12):1697–704.CrossRefPubMed

13.

Lucidarme O, Kono Y, Corbeil J, Choi SH, Golmard JL, Varner J, et al. Angiogenesis: noninvasive quantitative assessment with contrast-enhanced functional US in murine model. Radiology. 2006;239(3):730–9.CrossRefPubMed

14.

El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014;60(5):1767–75.CrossRefPubMedPubMedCentral

15.

Westwood M, Joore M, Grutters J, Redekop K, Armstrong N, Lee K, et al. Contrast-enhanced ultrasound using SonoVue(R) (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2013;17(16):1–243.CrossRef

16.

Tanaka H, Iijima H, Nouso K, Aoki N, Iwai T, Takashima T, et al. Cost-effectiveness analysis on the surveillance for hepatocellular carcinoma in liver cirrhosis patients using contrast-enhanced ultrasonography. Hepatol Res. 2012;42(4):376–84.CrossRefPubMed

17.

Moriyasu F, Itoh K. Efficacy of perflubutane microbubble-enhanced ultrasound in the characterization and detection of focal liver lesions: phase 3 multicenter clinical trial. AJR Am J Roentgenol. 2009;193(1):86–95.CrossRefPubMed

18.

Martie A, Sporea I, Popescu A, Sirli R, Danila M, Serban C, et al. Contrast enhanced ultrasound for the characterization of hepatocellular carcinoma. Med Ultrason. 2011;13(2):108–13.PubMed

19.

Zhang XY, Luo Y, Wen TF, Jiang L, Li C, Zhong XF, et al. Contrast-enhanced ultrasound: improving the preoperative staging of hepatocellular carcinoma and guiding individual treatment. World J Gastroenterol. 2014;20(35):12628–36.CrossRefPubMedPubMedCentral

20.

International Consensus Group for Hepatocellular NeoplasiaThe International Consensus Group for Hepatocellular N. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology. 2009;49(2):658–64.CrossRef

21.

Matsui O. Detection and characterization of hepatocellular carcinoma by imaging. Clin Gastroenterol Hepatol. 2005;3(10 Suppl 2):S136–40.CrossRefPubMed

22.

Quaia E, Calliada F, Bertolotto M, Rossi S, Garioni L, Rosa L, et al. Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble contrast agent: diagnostic performance and confidence. Radiology. 2004;232(2):420–30.CrossRefPubMed

23.

Kim TK, Lee KH, Khalili K, Jang HJ. Hepatocellular nodules in liver cirrhosis: contrast-enhanced ultrasound. Abdom Imaging. 2011;36(3):244–63.CrossRefPubMed

24.

Burns PN, Wilson SR. Focal liver masses: enhancement patterns on contrast-enhanced images—concordance of US scans with CT scans and MR images. Radiology. 2007;242(1):162–74.CrossRefPubMed

25.

Wilson SR, Kim TK, Jang HJ, Burns PN. Enhancement patterns of focal liver masses: discordance between contrast-enhanced sonography and contrast-enhanced CT and MRI. AJR Am J Roentgenol. 2007;189(1):W7–W12.CrossRefPubMed

26.

Tada T, Kumada T, Toyoda H, Ito T, Sone Y, Kaneoka Y, et al. Utility of contrast-enhanced ultrasonography with perflubutane for determining histologic grade in hepatocellular carcinoma. Ultrasound Med Biol. 2015;41(12):3070–8.CrossRefPubMed

27.

Numata K, Fukuda H, Nihonmatsu H, Kondo M, Nozaki A, Chuma M, et al. Use of vessel patterns on contrast-enhanced ultrasonography using a perflubutane-based contrast agent for the differential diagnosis of regenerative nodules from early hepatocellular carcinoma or high-grade dysplastic nodules in patients with chronic liver disease. Abdom Imaging. 2015;40(7):2372–83.CrossRefPubMed

28.

Jang HJ, Kim TK, Burns PN, Wilson SR. Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US: comparison with histologic differentiation. Radiology. 2007;244(3):898–906.CrossRefPubMed

29.

Numata K, Fukuda H, Miwa H, Ishii T, Moriya S, Kondo M, et al. Contrast-enhanced ultrasonography findings using a perflubutane-based contrast agent in patients with early hepatocellular carcinoma. Eur J Radiol. 2014;83(1):95–102.CrossRefPubMed

30.

Wilson SR, Burns PN. An algorithm for the diagnosis of focal liver masses using microbubble contrast-enhanced pulse-inversion sonography. AJR Am J Roentgenol. 2006;186(5):1401–12.CrossRefPubMed

31.

Goetti R, Reiner CS, Knuth A, Klotz E, Stenner F, Samaras P, et al. Quantitative perfusion analysis of malignant liver tumors: dynamic computed tomography and contrast-enhanced ultrasound. Invest Radiol. 2012;47(1):18–24.CrossRefPubMed

32.

Feng Y, Qin XC, Luo Y, Li YZ, Zhou X. Efficacy of contrast-enhanced ultrasound washout rate in predicting hepatocellular carcinoma differentiation. Ultrasound Med Biol. 2015;41(6):1553–60.CrossRefPubMed

33.

Pei XQ, Liu LZ, Liu M, Zheng W, Han F, Li AH, et al. Contrast-enhanced ultrasonography of hepatocellular carcinoma: correlation between quantitative parameters and histological grading. Br J Radiol. 2012;85(1017):e740–7.CrossRefPubMedPubMedCentral

34.

Takahashi M, Maruyama H, Ishibashi H, Yoshikawa M, Yokosuka O. Contrast-enhanced ultrasound with perflubutane microbubble agent: evaluation of differentiation of hepatocellular carcinoma. AJR Am J Roentgenol. 2011;196(2):W123–31.CrossRefPubMed

35.

Xu JF, Liu HY, Shi Y, Wei ZH, Wu Y. Evaluation of hepatocellular carcinoma by contrast-enhanced sonography: correlation with pathologic differentiation. J Ultrasound Med. 2011;30(5):625–33.PubMed

36.

Sugimoto K, Moriyasu F, Saito K, Taira J, Saguchi T, Yoshimura N, et al. Comparison of Kupffer-phase Sonazoid-enhanced sonography and hepatobiliary-phase gadoxetic acid-enhanced magnetic resonance imaging of hepatocellular carcinoma and correlation with histologic grading. J Ultrasound Med. 2012;31(4):529–38.PubMed

37.

Kondo T, Maruyama H, Kiyono S, Sekimoto T, Shimada T, Takahashi M, et al. Intensity-based assessment of microbubble-enhanced ultrasonography: phase-related diagnostic ability for cellular differentiation of hepatocellular carcinoma. Ultrasound Med Biol. 2015;41(12):3079–87.CrossRefPubMed

38.

Suzuki K, Okuda Y, Ota M, Kojima F, Horimoto M. Diagnosis of hepatocellular carcinoma nodules in patients with chronic liver disease using contrast-enhanced sonography: usefulness of the combination of arterial- and Kupffer-phase enhancement patterns. J Ultrasound Med. 2015;34(3):423–33.CrossRefPubMed

39.

Kim TK, Choi BI, Han JK, Hong HS, Park SH, Moon SG. Hepatic tumors: contrast agent-enhancement patterns with pulse-inversion harmonic US. Radiology. 2000;216(2):411–7.CrossRefPubMed

40.

D’Onofrio M, Crosara S, De Robertis R, Canestrini S, Mucelli RP. Contrast-enhanced ultrasound of focal liver lesions. AJR Am J Roentgenol. 2015;205(1):W56–66.CrossRefPubMed

41.

Guang Y, Xie L, Ding H, Cai A, Huang Y. Diagnosis value of focal liver lesions with SonoVue(R)-enhanced ultrasound compared with contrast-enhanced computed tomography and contrast-enhanced MRI: a meta-analysis. J Cancer Res Clin Oncol. 2011;137(11):1595–605.CrossRefPubMed

42.

Sugimoto K, Moriyasu F, Shiraishi J, Saito K, Taira J, Saguchi T, et al. Assessment of arterial hypervascularity of hepatocellular carcinoma: comparison of contrast-enhanced US and gadoxetate disodium-enhanced MR imaging. Eur Radiol. 2012;22(6):1205–13.CrossRefPubMed

43.

Takahashi M, Maruyama H, Shimada T, Kamezaki H, Sekimoto T, Kanai F, et al. Characterization of hepatic lesions (≤ 30 mm) with liver-specific contrast agents: a comparison between ultrasound and magnetic resonance imaging. Eur J Radiol. 2013;82(1):75–84.CrossRefPubMed

44.

Shin SK, Kim YS, Choi SJ, Shim YS, Jung DH, Kwon OS, et al. Contrast-enhanced ultrasound for the differentiation of small atypical hepatocellular carcinomas from dysplastic nodules in cirrhosis. Dig Liver Dis. 2015;47(9):775–82.CrossRefPubMed

45.

Shagdarsuren B, Tamai H, Shingaki N, Mori Y, Maeshima S, Nuta J, et al. Contribution of contrast-enhanced sonography with perfluorobutane microbubbles for diagnosis of recurrent hepatocellular carcinoma. J Ultrasound Med. 2016;35(7):1383–91.CrossRefPubMed

46.

• D’Onofrio M, Crosara S, De Robertis R, Canestrini S, Cantisani V, Morana G, et al. Malignant focal liver lesions at contrast-enhanced ultrasonography and magnetic resonance with hepatospecific contrast agent. Ultrasound. 2014;22(2):91–8. Emphasizes the synergy of using both MR and CEUS to improve diagnosis of HCC.CrossRefPubMed

47.

Catalano O, Izzo F, Vallone P, Sandomenico F, Albino V, Nunziata A, et al. Integrating contrast-enhanced sonography in the follow-up algorithm of hepatocellular carcinoma treated with radiofrequency ablation: single cancer center experience. Acta Radiol. 2015;56(2):133–42.CrossRefPubMed

48.

Shah A, Tang A, Santillan C, Sirlin C. Cirrhotic liver: what’s that nodule? The LI-RADS approach. J Magn Reson Imaging. 2016;43(2):281–94.CrossRefPubMed

49.

Radiology. ACo. CEUS liver imaging reporting and data system version 2016. 2016.

50.

Barreiros AP, Piscaglia F, Dietrich CF. Contrast enhanced ultrasound for the diagnosis of hepatocellular carcinoma (HCC): comments on AASLD guidelines. J Hepatol. 2012;57(4):930–2.CrossRefPubMed

51.

Liu GJ, Wang W, Lu MD, Xie XY, Xu HX, Xu ZF, et al. Contrast-enhanced ultrasound for the characterization of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Liver Cancer. 2015;4(4):241–52.CrossRefPubMedPubMedCentral

52.

• Li R, Yuan MX, Ma KS, Li XW, Tang CL, Zhang XH, et al. Detailed analysis of temporal features on contrast enhanced ultrasound may help differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma in cirrhosis. PLoS One. 2014;9(5):e98612. Examined temporal characteristics of liver lesions to distinguish between HCC and cholangiocarcinoma, a diagnosis that has traditionally been difficult to make on CEUS.CrossRefPubMedPubMedCentral

53.

Han J, Liu Y, Han F, Li Q, Yan C, Zheng W, et al. The degree of contrast washout on contrast-enhanced ultrasound in distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma. Ultrasound Med Biol. 2015;41(12):3088–95.CrossRefPubMed

54.

Li R, Yang D, Tang CL, Cai P, Ma KS, Ding SY, et al. Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography. BMC Cancer. 2016;16:158.CrossRefPubMedPubMedCentral

55.

Kong WT, Wang WP, Huang BJ, Ding H, Mao F. Value of wash-in and wash-out time in the diagnosis between hepatocellular carcinoma and other hepatic nodules with similar vascular pattern on contrast-enhanced ultrasound. J Gastroenterol Hepatol. 2014;29(3):576–80.CrossRefPubMed

56.

Minagawa M, Makuuchi M, Takayama T, Ohtomo K. Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg. 2001;233(3):379–84.CrossRefPubMedPubMedCentral

57.

Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29(1):62–7.CrossRefPubMed

58.

Piscaglia F, Gianstefani A, Ravaioli M, Golfieri R, Cappelli A, Giampalma E, et al. Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. Liver Transpl. 2010;16(5):658–67.PubMed

59.

Dodd 3rd GD, Memel DS, Baron RL, Eichner L, Santiguida LA. Portal vein thrombosis in patients with cirrhosis: does sonographic detection of intrathrombus flow allow differentiation of benign and malignant thrombus? AJR Am J Roentgenol. 1995;165(3):573–7.CrossRefPubMed

60.

• Raza SA, Jang HJ, Kim TK. Differentiating malignant from benign thrombosis in hepatocellular carcinoma: contrast-enhanced ultrasound. Abdom Imaging. 2014;39(1):153–61. Demonstrated the high diagnostic accuracy of CEUS for distinguishing between malignant and benign thrombosis, the former having significant clinical and prognostic implications.CrossRefPubMed

61.

Tarantino L, Francica G, Sordelli I, Esposito F, Giorgio A, Sorrentino P, et al. Diagnosis of benign and malignant portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma: color Doppler US, contrast-enhanced US, and fine-needle biopsy. Abdom Imaging. 2006;31(5):537–44.CrossRefPubMed

62.

Rossi S, Rosa L, Ravetta V, Cascina A, Quaretti P, Azzaretti A, et al. Contrast-enhanced versus conventional and color Doppler sonography for the detection of thrombosis of the portal and hepatic venous systems. AJR Am J Roentgenol. 2006;186(3):763–73.CrossRefPubMed

63.

Rossi S, Ghittoni G, Ravetta V, Torello Viera F, Rosa L, Serassi M, et al. Contrast-enhanced ultrasonography and spiral computed tomography in the detection and characterization of portal vein thrombosis complicating hepatocellular carcinoma. Eur Radiol. 2008;18(8):1749–56.CrossRefPubMed

64.

• Rajesh S, Mukund A, Arora A, Jain D, Sarin SK. Contrast-enhanced US-guided radiofrequency ablation of hepatocellular carcinoma. J Vasc Interv Radiol. 2013;24(8):1235–40. This study shows how CEUS can better demonstrate lesions that are not well seen on unenhanced US or CT, thus providing improved guidance for ablation.CrossRefPubMed

65.

Yoon SH, Lee KH, Kim SY, Kim YH, Kim JH, Lee SH, et al. Real-time contrast-enhanced ultrasound-guided biopsy of focal hepatic lesions not localised on B-mode ultrasound. Eur Radiol. 2010;20(8):2047–56.CrossRefPubMed

66.

Chan AK, Hegarty C, Klass D, Yoshida E, Chung S, Liu DM, et al. The role of contrast-enhanced ultrasound in guiding radiofrequency ablation of hepatocellular carcinoma: a retrospective study. Can Assoc Radiol J. 2015;66(2):171–8.CrossRefPubMed

67.

Liu M, Lin MX, Lu MD, Xu ZF, Zheng KG, Wang W, et al. Comparison of contrast-enhanced ultrasound and contrast-enhanced computed tomography in evaluating the treatment response to transcatheter arterial chemoembolization of hepatocellular carcinoma using modified RECIST. Eur Radiol. 2015;25(8):2502–11.CrossRefPubMed

68.

Shaw CM, Eisenbrey JR, Lyshchik A, O’Kane PL, Merton DA, Machado P, et al. Contrast-enhanced ultrasound evaluation of residual blood flow to hepatocellular carcinoma after treatment with transarterial chemoembolization using drug-eluting beads: a prospective study. J Ultrasound Med. 2015;34(5):859–67.CrossRefPubMed

69.

Kono Y, Lucidarme O, Choi SH, Rose SC, Hassanein TI, Alpert E, et al. Contrast-enhanced ultrasound as a predictor of treatment efficacy within 2 weeks after transarterial chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol. 2007;18(1 Pt 1):57–65.CrossRefPubMed

70.

• Takizawa K, Numata K, Morimoto M, Kondo M, Nozaki A, Moriya S, et al. Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma. Eur J Radiol. 2013;82(9):1471–80. This study showed that CEUS one day after TACE was more accurate than CECT at one month. This is significant as it provides quicker feedback and follow-up for HCC lesions that have not responded to therapy.CrossRefPubMed

71.

Cho YZ, Park SY, Choi EH, Baik SK, Kwon SO, Kim YJ, et al. The usefulness of contrast-enhanced ultrasonography in the early detection of hepatocellular carcinoma viability after transarterial chemoembolization: pilot study. Clin Mol Hepatol. 2015;21(2):165–74.CrossRefPubMedPubMedCentral

72.

Wang Y, Jing X, Ding J. Clinical value of dynamic 3-dimensional contrast-enhanced ultrasound imaging for the assessment of hepatocellular carcinoma ablation. Clin Imaging. 2016;40(3):402–6.CrossRefPubMed

73.

Qu P, Yu X, Liang P, Cheng Z, Han Z, Liu F, et al. Contrast-enhanced ultrasound in the characterization of hepatocellular carcinomas treated by ablation: comparison with contrast-enhanced magnetic resonance imaging. Ultrasound Med Biol. 2013;39(9):1571–9.CrossRefPubMed

74.

Inoue T, Kudo M, Hatanaka K, Arizumi T, Takita M, Kitai S, et al. Usefulness of contrast-enhanced ultrasonography to evaluate the post-treatment responses of radiofrequency ablation for hepatocellular carcinoma: comparison with dynamic CT. Oncology. 2013;84 Suppl 1:51–7.CrossRefPubMed

75.

Lekht I, Gulati M, Nayyar M, Katz MD, Ter-Oganesyan R, Marx M, et al. Role of contrast-enhanced ultrasound (CEUS) in evaluation of thermal ablation zone. Abdom Radiol (NY). 2016;41(8):1511–21.CrossRef

76.

Li K, Su ZZ, Xu EJ, Ju JX, Meng XC, Zheng RQ. Improvement of ablative margins by the intraoperative use of CEUS-CT/MR image fusion in hepatocellular carcinoma. BMC Cancer. 2016;16:277.CrossRefPubMedPubMedCentral

77.

Mitsunori Y, Tanaka S, Nakamura N, Ban D, Irie T, Noguchi N, et al. Contrast-enhanced intraoperative ultrasound for hepatocellular carcinoma: high sensitivity of diagnosis and therapeutic impact. J Hepatobiliary Pancreat Sci. 2013;20(2):234–42.CrossRefPubMed

78.

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.CrossRefPubMed

79.

Zhou JH, Cao LH, Liu JB, Zheng W, Liu M, Luo RZ, et al. Quantitative assessment of tumor blood flow in mice after treatment with different doses of an antiangiogenic agent with contrast-enhanced destruction-replenishment US. Radiology. 2011;259(2):406–13.CrossRefPubMed

80.

Zhou JH, Zheng W, Cao LH, Liu M, Luo RZ, Han F, et al. Contrast-enhanced ultrasonic parametric perfusion imaging in the evaluation of antiangiogenic tumor treatment. Eur J Radiol. 2012;81(6):1360–5.CrossRefPubMed

81.

Zhu XD, Zhang JB, Fan PL, Xiong YQ, Zhuang PY, Zhang W, et al. Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography. BMC Cancer. 2011;11:28.CrossRefPubMedPubMedCentral

82.

Moschouris H, Malagari K, Gkoutzios P, Kalokairinou M, Stamatiou K, Chatzimichail K, et al. Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography. Med Ultrason. 2012;14(2):87–94.PubMed

83.

Zocco MA, Garcovich M, Lupascu A, Di Stasio E, Roccarina D, Annicchiarico BE, et al. Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound. J Hepatol. 2013;59(5):1014–21.CrossRefPubMed

84.

Sugimoto K, Moriyasu F, Saito K, Rognin N, Kamiyama N, Furuichi Y, et al. Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US. Liver Int. 2013;33(4):605–15.CrossRefPubMed

85.

Frampas E, Lassau N, Zappa M, Vullierme MP, Koscielny S, Vilgrain V. Advanced hepatocellular carcinoma: early evaluation of response to targeted therapy and prognostic value of perfusion CT and dynamic contrast enhanced-ultrasound. Preliminary results. Eur J Radiol. 2013;82(5):e205–11.CrossRefPubMed

86.

Lassau N, Koscielny S, Chami L, Chebil M, Benatsou B, Roche A, et al. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification—preliminary results. Radiology. 2011;258(1):291–300.CrossRefPubMed

87.

Lo GM, Al Zahrani H, Jang HJ, Menezes R, Hudson J, Burns P, et al. Detection of early tumor response to axitinib in advanced hepatocellular carcinoma by dynamic contrast enhanced ultrasound. Ultrasound Med Biol. 2016;42(6):1303–11.CrossRefPubMed

88.

Sugimoto K, Moriyasu F, Negishi Y, Hamano N, Oshiro H, Rognin NG, et al. Quantification in molecular ultrasound imaging: a comparative study in mice between healthy liver and a human hepatocellular carcinoma xenograft. J Ultrasound Med. 2012;31(12):1909–16.PubMed

89.

Baron Toaldo M, Salvatore V, Marinelli S, Palama C, Milazzo M, Croci L, et al. Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma. Mol Imaging Biol. 2015;17(1):29–37.CrossRefPubMed

90.

Sirsi SR, Borden MA. Advances in ultrasound mediated gene therapy using microbubble contrast agents. Theranostics. 2012;2(12):1208–22.CrossRefPubMedPubMedCentral

91.

• Mullick Chowdhury S, Wang TY, Bachawal S, Devulapally R, Choe JW, Abou Elkacem L, et al. Ultrasound-guided therapeutic modulation of hepatocellular carcinoma using complementary microRNAs. J Control Release. 2016;238:272–80. This preclinical study showed the feasibility of deliverying complementary microRNAs to HCC, resulting in improved efficiency of treatment of doxorubicin resistant HCC.CrossRefPubMed

92.

Zhu F, Jiang Y, Luo F, Li P. Effectiveness of localized ultrasound-targeted microbubble destruction with doxorubicin liposomes in H22 mouse hepatocellular carcinoma model. J Drug Target. 2015;23(4):323–34.CrossRefPubMed

93.

Li J, Zhou P, Li L, Zhang Y, Shao Y, Tang L, et al. Effects of cationic microbubble carrying CD/TK double suicide gene and alphaVbeta3 integrin antibody in human hepatocellular carcinoma HepG2 cells. PLoS One. 2016;11(7):e0158592.CrossRefPubMedPubMedCentral

Titel: Contrast-Enhanced Ultrasound (CEUS) for the Diagnosis and Management of Hepatocellular Carcinoma: Current Status and Future Trends
verfasst von: Christopher D. Malone
Robert F. Mattrey
David T. Fetzer
Publikationsdatum: 04.11.2016
Verlag: Springer US
Erschienen in: Current Hepatology Reports / Ausgabe 4/2016
Elektronische ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-016-0324-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2016

Future Therapy for Hepatitis B Virus: Role of Nucleos(t)ide Analogues and Pegylated Interferon Therapy

Future Therapy for Hepatitis B Virus: Role of Immunomodulators

Future Therapy for HBV: Role of Cell Cycle Inhibitors

Management of Direct-Acting Antiviral Failures in Chronic Hepatitis C Infection

Hepatitis C and Hepatocellular Carcinoma